Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) signed share transfer contract to acquire remaining 2% stake in Shenzhen Salubris Biomedical Engineering Co., Ltd. from Shenzhen National Independent Innovation Demonstration Zone Services Center for CNY 7.3 million recently. Pre deal, Shenzhen Salubris Pharmaceuticals Co., Ltd. owned 98% stake and post deal, it will own 100% stake in Shenzhen Salubris Biomedical Engineering Co., Ltd. As of December 31, 2017, Shenzhen Salubris Biomedical Engineering Co., Ltd. reported total assets of CNY 103 million and net assets of CNY 87.9 million, revenues as nil, operating loss of CNY 19.5 million and net loss of CNY 19.6 million. The deal does not need the approvals of Shenzhen Salubris Pharmaceuticals Co., Ltd.'s Directorate and shareholders.